# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-119262
**Filing Date:** 2025-12
**Character Count:** 21584
**Document Hash:** 958b23931b9e1537dbbe3ae7b76ab045
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-119262.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001213900-25-119262

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**EFFECTIVENESS DATE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292003
- **FILM NUMBER:** 251556542

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

**As filed with the Securities and Exchange Commission on December 8, 2025**

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

 ****

**INMED PHARMACEUTICALS INC.** 

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **British Columbia** | **98-1428279** |
| **(State or other jurisdiction of**<br> **incorporation or organization)**  | **(I.R.S Employer**<br> **Identification No.)**  |

---

**Suite 1445 - 885 W. Georgia Street**

**Vancouver, British Columbia V6C 3E8**

**Canada**

**(604) 669-7207**

(Address, including zip code and telephone number, including area code, of registrant's principal executive offices)

**InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan**

(Full title of the plan)

**Registered Agent Solutions, Inc.**

**1100 H Street NW**, **Suite 840**

**Washington, DC 20005**

**(888) 705-7274**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

 ****

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Netta Jagpal**<br> **Chief Financial Officer**<br> **InMed Pharmaceuticals Inc.**<br> **Suite 1445 – 885 West Georgia St.** <br> **Vancouver, British Columbia, Canada V6C 3E8** <br> **(604) 669-7207** | &nbsp;&nbsp;**Scott Saks**<br> **Norton Rose Fulbright US LLP**<br> **1301 Avenue of the Americas**<br> **New York NY 10019-6022**<br> **United States**<br> **(212) 318-3151** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

The purpose of this registration statement on Form S-8 (this "Registration Statement") is to register an additional 300,000 common shares, no par value (the "Common Shares"), of InMed Pharmaceuticals Inc. (the "Company"), for allotment under the InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (the "2017 Stock Option Plan"). On December 5, 2025, the board of directors of the Company approved the reservation of an additional 300,000 Common Shares for allotment under the 2017 Stock Option Plan.

In accordance with General Instruction E of Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), the contents of (i) the Company's registration statement on Form S-8 (File No. 333-253912), filed with the Securities and Exchange Commission (the "Commission") on March 5, 2021, to register 2,088 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (ii) the Company's registration statement on Form S-8 (File No. 333-260323), filed with the Commission on October 18, 2021, to register an additional 1,600 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (iii) the Company's registration statement on Form S-8 (File No. 333-268356), filed with the Commission on November 14, 2022, to register an additional 4,000 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (iv) the Company's registration statement on Form S-8 (File No. 333-276212), filed with the Commission on December 22, 2023, to register an additional 35,000 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, and (iv) the Company's registration statement on Form S-8 (File No. 333-283951), filed with the Commission on December 20, 2024, to register an additional 60,000 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, are each incorporated herein by reference, except to the extent supplemented, amended and superseded by the information set forth herein.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

Except to the extent that information is deemed furnished and not filed pursuant to securities laws and regulations, the following documents, which have been previously filed with the Commission, are incorporated by reference into this Registration Statement:

● our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, initially filed with the Commission on [September 23, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/ea0253959-10k_inmed.htm) and as amended on [October 24, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025102157/ea0262392-10ka1_inmed.htm) ;

● our Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/ix?doc=/Archives/edgar/data/1728328/000121390025104914/ea0262858-def14a_inmed.htm) , filed with the Commission on November 3, 2025;

● our Quarterly Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1728328/000121390025107152/ea0262541-10q_inmed.htm) for the quarter ended September 30, 2025, filed with the Commission on November 6, 2025;

● our Current Reports on Form 8-K, filed with the Commission on [September 23, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/ea0258458-8k_inmed.htm) , [October 14, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/ea0260877-8k_inmed.htm) , [October 14, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025098229/ea0261001-8k_inmed.htm) and [October 16, 2025](https://www.sec.gov/Archives/edgar/data/1728328/000121390025099529/ea0261537-8k_inmed.htm) ; and

● the description of our common shares in our Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1728328/000119312520285837/d72199d8a12b.htm) filed with the Commission on November 5, 2020, including any subsequent amendment thereto filed for the purpose of updating such description.

Except to the extent that information is deemed furnished and not filed pursuant to securities laws and regulations, all documents filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that (i) indicates that all securities offered under this Registration Statement have been sold, or (ii) deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents. In no event, however, will any information that we disclose under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form 8-K that we may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration Statement.

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 8.** | **Exhibits.** |

---

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 4.1 | [Amended and Restated Articles (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-239319), filed on June 19, 2020).](https://www.sec.gov/Archives/edgar/data/1728328/000119312520174157/d904092dex31.htm) |
| 4.2 | [InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).](https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-2_inmedpharma.htm) |
| 4.3 | [Form of Stock Option Agreement pursuant to InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).](https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-3_inmedpharma.htm) |
| 4.4 | [Form of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company's Form S-1 filed on July 13, 2021).](https://www.sec.gov/Archives/edgar/data/1728328/000121390021036589/ea144036ex4-3_inmedpha.htm) |
| 5.1\* | [Opinion of Norton Rose Fulbright Canada LLP regarding legality of securities being registered.](ea026870601ex5-1_inmed.htm) |
| 23.1\* | [Consent of CBIZ CPAs P.C.](ea026870601ex23-1_inmed.htm) |
| 23.2\* | [Consent of Marcum LLP](ea026870601ex23-2_inmed.htm) |
| 23.3\* | [Consent of Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1).](ea026870601ex5-1_inmed.htm) |
| 24.1\* | [Power of Attorney (included as part of signature page to this Registration Statement).](#toc) |
| 107.1\* | [Calculation of Filing Fee Tables](ea026870601ex-fee_inmed.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, InMed Pharmaceuticals Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, British Columbia, Canada, on December 8, 2025.

---

| | |
|:---|:---|
| **INMED PHARMACEUTICALS INC.** | **INMED PHARMACEUTICALS INC.** |
| By: | /s/ Netta Jagpal |
|  | Netta Jagpal |
|  | Chief Financial Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below, the undersigned officers and directors of InMed Pharmaceuticals Inc., hereby severally constitute and appoint Eric A. Adams and Netta Jagpal, and each of them singly (with full power to each of them to act alone), his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him (or her) and in his (or her) name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his (or her) substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated on December 8, 2025.

---

| | |
|:---|:---|
| **Name** | **Title** |
| /s/ Eric A. Adams | President, Chief Executive Officer and Director |
| Eric A. Adams | (principal executive officer) |
| /s/ Netta Jagpal | Chief Financial Officer |
| Netta Jagpal | (principal financial officer and principal accounting officer) |
| /s/ Bryan Baldasare | Director |
| Bryan Baldasare | |
| /s/ Andrew Hull | Director |
| Andrew Hull |  |
| /s/ Nicole Lemerond | Director |
| Nicole Lemerond |  |
| /s/ Neil Klompas | Director |
| Neil Klompas |  |
| /s/ John Bathery | Director |
| John Bathery |  |

---

**AUTHORIZED REPRESENTATIVE**

Pursuant to the requirements to Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement solely in the capacity of the duly authorized representative of InMed Pharmaceuticals Inc. in the United States on December 8, 2025.

---

| | |
|:---|:---|
| By: | /s/ Andrew Hull |
|  | Andrew Hull |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
|  | ![](ex5-1_001.jpg) |
| December 8, 2025 |  |
| **InMed Pharmaceuticals Inc.** | Norton Rose Fulbright Canada LLP |
| Suite 310 – 815 West Hastings Street | 222 Bay Street, Suite 3000, P.O. Box 53 |
| Vancouver, BC V6C 1B4 | Toronto, Ontario M5K 1E7 Canada |
|  | F: +1 416.216.3930 |
|  | **nortonrosefulbright.com** |

---

**Re: Registration Statement of InMed Pharmaceuticals Inc. on Form S-8**

Dear Sirs/Mesdames:

We have acted as counsel to InMed Pharmaceuticals Inc. (the **Company**), a corporation incorporated under the laws of the Province of British Columbia, in connection with the registration under the United States Securities Act of 1933, as amended (the **Securities Act**), pursuant to a Registration Statement on Form S- 8 (the **Registration Statement**), filed on or about the date hereof with the United States Securities and Exchange Commission (the **SEC**), of up to an aggregate of 300,000 common shares of the Company (the **Common Shares**) which are issuable by the Company to eligible participants pursuant to stock options granted under the 2017 Stock Option Plan of the Company, as amended, (the **Stock Option Plan**).

As counsel, we have made such investigations and examined the originals, or duplicate, certified, conformed, telecopied or photostatic copies of such corporate records, agreements, documents and other instruments and have made such other investigations as we have considered necessary or relevant for the purposes of this opinion, including:

&nbsp;&nbsp;&nbsp;&nbsp;a) the Registration Statement and the Stock Option Plan;

&nbsp;&nbsp;&nbsp;&nbsp;b) the articles and notice of articles of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;c) certain resolutions of the Company's board of directors;
and

&nbsp;&nbsp;&nbsp;&nbsp;d) a Certificate of Good Standing dated December 5, 2025 issued
by the Registrar of Companies in British Columbia.

With respect to the accuracy of factual matters material to this opinion, we have relied upon certificates or comparable documents and representations of public officials and of officers of the Company and have not performed any independent check or verification of such factual matters.

In giving this opinion, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as duplicates, certified, conformed, telecopied or photostatic copies and the authenticity of the originals of such latter documents. We have also assumed that the Certificate of Good Standing referred to above will continue to be accurate as at the date of issuance of any Common Shares issued under the Registration Statement.

The opinion set forth below is limited to the laws of the Province of British Columbia and the federal laws of Canada applicable therein, in each case in effect on the date hereof. Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention.

Where our opinion below refers to the Common Shares as being "fully-paid and non-assessable", such opinion assumes that all required consideration (in whatever form) has been or will be paid or provided. No opinion is expressed as to the adequacy of any consideration received.

![](ex5-1_002.jpg)

Based on the foregoing, and subject to the assumptions, limitations and qualifications set forth herein, we are of the opinion that upon issuance and delivery of and payment for such Common Shares in accordance with the terms and conditions of the Registration Statement and the Stock Option Plan, such Common Shares being issued by the Company, will be validly issued, fully paid and non-assessable shares in the share capital of the Company.

This opinion has been prepared for your use in connection with the Registration Statement and is expressed as of the date hereof. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Registration Statement or the Common Shares.

We hereby consent to the filing of this opinion with the SEC as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the SEC promulgated thereunder. This opinion may not be quoted from or referred to in any documents other than the Registration Statement as provided for herein without our prior written consent.

Yours truly,

/s/ Norton Rose Fulbright Canada LLP

Norton Rose Fulbright Canada LLP

## Exhibit 23.1

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated September 22, 2025, with respect to the consolidated financial statements of InMed Pharmaceuticals, Inc. included in the Annual Report on Form 10-K for the year ended June 30, 2025.

/s/ CBIZ CPAs P.C

New York, NY

December 8, 2025

## Exhibit 23.2

**Exhibit 23.2**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated September 27, 2024, except for the effects of Note 14, Reverse Stock Split, as to which the date is July 31, 2025, with respect to the consolidated financial statements of InMed Pharmaceuticals, Inc. included in the Annual Report on Form 10-K for the year ended June 30, 2024.

/s/ Marcum LLP

New York, NY

December 8, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**InMed Pharmaceuticals Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common shares, no par value | (1) | Other | 300000 | $1.31 | $393000.00 | 0.0001381 | $54.28 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $393000.00 |  | 54.28 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $54.28 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents additional common shares, no par value, of InMed Pharmaceuticals Inc. ("Common Shares"), reserved for future issuances under the InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (the "2017 Stock Option Plan"). This Registration Statement also includes such additional number of Common Shares, as may be required in the event of a stock split, stock dividend or similar transaction in accordance with Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"). Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, based upon the average of the high and low prices of the Common Shares as reported on the Nasdaq Capital Market on December 4, 2025.